Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine...

詳細記述

保存先:
書誌詳細
主要な著者: Byrd, John C., Lin, Thomas S., Dalton, James T., Wu, Di, Phelps, Mitch A., Fischer, Beth, Moran, Mollie, Blum, Kristie A., Rovin, Brad, Brooker-McEldowney, Michelle, Broering, Sarah, Schaaf, Larry J., Johnson, Amy J., Lucas, David M., Heerema, Nyla A., Lozanski, Gerard, Young, Donn C., Suarez, Jose-Ramon, Colevas, A. Dimitrios, Grever, Michael R.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2007
主題:
Plenary Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785084/
https://ncbi.nlm.nih.gov/pubmed/17003373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-05-020735
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料